Nature Reviews Gastroenterology & Hepatology
Despite the Middle East and North Africa having the highest global burden of metabolic dysfunction-associated steatotic liver disease, patients from this region remain markedly under-represented in the disease clinical drug trials. Addressing this gap is essential for ensuring equitable access to novel therapies and enhancing global liver health.
Full Article Here: https://www.nature.com/articles/s41575-025-01081-9